![]() |
市場調査レポート
商品コード
365802
可溶性グアニル酸シクラーゼ:パイプライン製品の分析Soluble Guanylate Cyclase - Pipeline Review, H2 2020 |
可溶性グアニル酸シクラーゼ:パイプライン製品の分析 |
出版日: 2020年11月30日
発行: Global Markets Direct
ページ情報: 英文 108 Pages
納期: 即納可能
![]() |
当レポートでは、可溶性グアニル酸シクラーゼを標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase - Pipeline Review, H2 2020, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 4, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Infectious Disease, Oncology, Gastrointestinal, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Glaucoma, Coronavirus Disease 2019 (COVID-19), Pulmonary Arterial Hypertension, Diabetic Nephropathy, Lung Disease, Ocular Hypertension, Vaso-Occlusive Crisis Associated With Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Chronic Kidney Disease (Chronic Renal Failure), Chronic Obstructive Pulmonary Disease (COPD), Chronic Thromboembolic Pulmonary Hypertension, Colorectal Cancer, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Retinopathy, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Ischemic Stroke, Liver Diseases, Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Pneumonia, Pressure Ulcers, Prostate Cancer, Pulmonary Hypertension, Raynauds Disease, Skin Ulcers, Stroke, Systolic Heart Failure and Vascular Dementias.
Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.